• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Medical Device Market
    Medical Device News
    Medical Device Stocks
    • Medical Device Market
    • Medical Device News
    • Medical Device Stocks
    medical device investing

    Vycor Medical Posts Financial Results for Q1 2017

    Bryan Mc Govern
    May. 12, 2017 08:41AM PST
    Medical Device Investing

    Vycor Medical released their financial report for the first quarter of 2017.

    Vycor Medical (OTCQB:VYCO) released their financial report for the first quarter of 2017.
    As quoted in the press release:

    Vycor’s revenues for the period ended March 31, 2017 were $428,000, compared to $400,000 for 2016. Cash Operating Loss1 was $87,000, as compared to $197,000 for the same period in 2016, a reduction of 56% and Operating Loss was $300,000, compared to $515,000, a reduction of 42%.
    Management Commentary
    “Vycor’s results show the Company continuing to deliver on its publicly stated strategic plan, with VBAS increasing its market adoption particularly in the US, aided by increased clinical data. NovaVision’s patient volumes have now outstripped the impact of our lowered pricing to patients, so we are now seeing an improvement in revenues. We continue to decrease our Cash Operating Loss2, which reduced to $87,000 for the quarter compared to $197,000 for the same period in 2016,” said Peter Zachariou, CEO of Vycor Medical.
    Period Ended March 31, 2017 Financial Results
    Revenue totaled $428,000 in the period ended March 31, 2017, as compared to $400,000 for the prior year, an increase of 7%. Vycor Medical’s revenue in the period increased by $21,000 to $370,000, reflecting increased sales in the US offset by lower sales internationally, with gross margin of 89% versus 82% for the same period in 2016. NovaVision sales grew by 14% with new VRT/Suite patient starts for the period increasing by 54% over the same period in 2016.
    Operating Expenses in the period ended March 31, 2017 totaled $680,000, as compared to $848,000 in the prior year period, a reduction of 20%, and Cash Operating Expenses3 were $467,000, as compared to $530,000, a reduction of 12%. Operating Loss was $300,000, compared to $515,000 for the same period in 2016, a reduction of 42%, and Cash Operating Loss2 was $87,000, as compared to $197,000, a reduction of 56%.
    Net Loss for the period ended March 31, 2017 was $313,000, as compared to $528,000 in 2016.

    Click here to read the full press release.

    Source: www.accesswire.com

    financial reportclinical datafinancial resultsmedical device investing
    The Conversation (0)

    Go Deeper

    AI Powered
    AbbVie Reports Second-Quarter 2025 Financial Results

    AbbVie Reports Second-Quarter 2025 Financial Results

    InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

    InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Medical Device Investing Stocks

    Cardiex Limited

    CDX:AU
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×